What's Happening?
Rosen Law Firm has issued a reminder to investors who purchased American Depositary Shares of Reckitt Benckiser Group PLC between January 13, 2021, and July 28, 2024, about the August 4, 2025 deadline to serve as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Reckitt failed to disclose the increased risk of necrotizing enterocolitis in preterm infants consuming its Enfamil formula, impacting sales and exposing the company to legal claims. Investors are encouraged to join the class action to seek compensation.
AD
Why It's Important?
The lawsuit highlights significant allegations against Reckitt Benckiser, which could have substantial financial implications for the company and its investors. If successful, the class action could lead to compensation for affected shareholders and potentially influence Reckitt's business practices and product disclosures. The case underscores the importance of transparency in corporate communications and the potential consequences of misleading statements.
What's Next?
Investors interested in leading the lawsuit must act before the August 4, 2025 deadline. The case will proceed with the selection of a lead plaintiff, who will represent the class in directing the litigation. The outcome of the lawsuit could affect Reckitt's financial standing and reputation, prompting potential changes in its product safety disclosures and business strategies.
